Beam Therapeutics (BEAM) Current Leases (2019 - 2026)

Beam Therapeutics (BEAM) has reported Current Leases for 8 consecutive years, with $14.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases rose 11.89% year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $14.8 million (up 11.89% YoY), while the FY2025 annual figure was $14.4 million, up 6.64% from the prior year.
• Current Leases climbed to $14.8 million in Q1 2026 per BEAM's latest filing, from $14.4 million in the prior quarter.
• Across five years, Current Leases topped out at $14.8 million in Q1 2026 and bottomed at $912000.0 in Q2 2023.
• Historically, Current Leases has averaged $10.4 million across 5 years, with a median of $12.6 million in 2024.
• Annual changes were most pronounced in 2023 — Current Leases tumbled 88.96% — and 2024, when it jumped 1286.07%.
• Beam Therapeutics' Current Leases stood at $10.4 million in 2022, then advanced by 23.1% to $12.8 million in 2023, then increased by 5.41% to $13.5 million in 2024, then gained by 6.64% to $14.4 million in 2025, then climbed by 2.9% to $14.8 million in 2026.
• Business Quant data shows BEAM's Current Leases at $14.8 million in Q1 2026, $14.4 million in Q4 2025, and $12.7 million in Q3 2025.